VK0214



NAME OF DRUG : VK0214

ALSO KNOWN AS : VK0214

LABORATORY : VIKING

STATUS AND ADVANCEMENT

Type of drug : TRβ agonist

Clinical trials advancement : Preclinic

Estimated time to market : 134 months.

LABORATORY ABSTRACT ON THE DRUG

NOT PROVIDED

RECENT NEWS ON VK0214

2017-10-24 : VKTX: Poster Presentations on VK2809 and VK0214 Highlight Positive Preclinical Data for Both Compounds...vs ELAFIBRANOR

SOME PUBLICATIONS RELATED WITH VK0214

SOME NASHBIOTECHS POINTS OF VIEW RELATED WITH VK0214


WWW.NASHBIOTECHS.COM  -  Copyright G DIVRY 2015-2016  - Contact and TERMS OF USE